European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.40% to 1,494.86 on the S&P Europe Select ADR Index, which is up 1.6% for the week.
From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and DBV Technologies (DBVT), which advanced 27% and 3.3%, respectively. They were followed by medical device maker EDAP (EDAP) and biopharmaceutical company Grifols (GRFS), which increased 2.1% and 1.3%, respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which fell 4.7% and 4.1%, respectively. They were followed by petroleum refiner Equinor (EQNR) and accommodations booking company trivago (TRVG), which dropped 1.2% and 1%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and pharmaceutical company Silence Therapeutics (SLN), which rose 4.8% and 2.3%, respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and financial services company Lloyds Banking Group (LYG), which were up 1.7% and 1.5%, respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and mining company BHP Group (BHP), which were down 4% and 1.8%, respectively. They were followed by pharmaceutical company GSK (GSK) and telecommunications operator Vodafone Group (VOD), which lost 1.7% each.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。